This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Piramal, Ajinomoto Collaborate on...
Business strategic collaboration

Piramal, Ajinomoto Collaborate on ADC Manufacturing

Analysis based on 11 articles · First reported Apr 16, 2026 · Last updated Apr 16, 2026

Sentiment
70
Attention
4
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The collaboration between Piramal Enterprises — Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services is expected to positively impact the pharmaceutical and biotechnology markets by accelerating the development and manufacturing of Antibody-Drug Conjugates (ADCs). This partnership will likely enhance the market positions of Piramal Group and Ajinomoto by expanding their service offerings and technological capabilities in a high-growth segment.

Pharmaceuticals Biotechnology
Event Summary

Piramal Enterprises — Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services have announced a strategic collaboration to enhance their customers' Antibody-Drug Conjugate (ADC) development and manufacturing programs. Under this agreement, Piramal Enterprises — Piramal Pharma Solutions will refer customers seeking ADC manufacturing technology to Ajinomoto Bio-Pharma Services and its AJICAP technology, while Ajinomoto Bio-Pharma Services will refer customers to Piramal Enterprises — Piramal Pharma Solutions for manufacturing products using AJICAP technology. A Material Transfer Agreement (MTA) will facilitate technology transfer, enabling Piramal Enterprises — Piramal Pharma Solutions to manufacture AJICAP-based products. This partnership combines Piramal Enterprises — Piramal Pharma Solutions' extensive experience as an FDA-approved ADC CDMO with Ajinomoto Bio-Pharma Services' innovative AJICAP technology, aiming to deliver more effective and precise ADC therapies.

Entities Involved
priv
Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services collaborated with Piramal Enterprises — Piramal Pharma Solutions to support ADC development and manufacturing, leveraging its AJICAP technology and expanding its ecosystem.
Importance 100.0 Sentiment 75.0
subs
Piramal Enterprises — Piramal Pharma Solutions
Piramal Enterprises — Piramal Pharma Solutions entered a strategic collaboration with Ajinomoto Bio-Pharma Services to enhance ADC development and manufacturing programs, expanding its capabilities and market reach.
Importance 100.0 Sentiment 75.0
stock
Piramal Group
Piramal Group's subsidiary, Piramal Enterprises — Piramal Pharma Solutions, entered a strategic collaboration, which is expected to positively impact the parent company's market position and offerings.
Importance 80.0 Sentiment 60.0
stock
Ajinomoto
Ajinomoto's subsidiary, Ajinomoto Bio-Pharma Services, formed a strategic collaboration, which is likely to enhance the parent company's standing in the biopharmaceutical sector.
Importance 80.0 Sentiment 60.0
per
Yasuyuki Otake
Yasuyuki Otake, Corporate Executive at Ajinomoto, emphasized that the collaboration expands the ecosystem supporting AJICAP technology and provides streamlined pathways for customers.
Importance 20.0 Sentiment 0.0
per
Peter DeYoung
Peter DeYoung, CEO of Piramal Global Pharma, expressed excitement about the collaboration, highlighting its potential to accelerate innovation and expand access to technology.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.